Angel Fernandez-Ramirez

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

A Drug-Gated, Modular STAb-T Immunotherapy With External Control.

A Drug-Gated, Modular STAb-T Immunotherapy With External Control.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: January 22, 2026

mRNA-engineered T lymphocytes secreting bispecific T cell engagers with therapeutic potential in solid tumors.

mRNA-engineered T lymphocytes secreting bispecific T cell engagers with therapeutic potential in solid tumors.

Journal: Frontiers in immunology
Published: August 12, 2025

CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression.

CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression.

Journal: Journal for immunotherapy of cancer
Published: April 07, 2025

Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers.

Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers.

Journal: Oncoimmunology
Published: December 26, 2024

CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts.

CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts.

Journal: Oncoimmunology
Published: August 29, 2024

Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.

Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.

Journal: Science translational medicine
Published: February 14, 2024

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.

Journal: Oncoimmunology
Published: April 28, 2023

Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.

Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.

Journal: Oncoimmunology
Published: March 31, 2022

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.

Journal: Cancer immunology research
Published: October 07, 2021

An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.

An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 28, 2020

IL-6-based mortality risk model for hospitalized patients with COVID-19.

IL-6-based mortality risk model for hospitalized patients with COVID-19.

Journal: The Journal of allergy and clinical immunology
Published: June 16, 2020

Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies.

Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies.

Journal: Frontiers in immunology
Published: May 17, 2020
Showing 1-12 of 12

Last Updated: 09/26/2026